R

Reata Pharmaceuticals Inc
F:2R3

Watchlist Manager
Reata Pharmaceuticals Inc
F:2R3
Watchlist
Price: 161 EUR
Market Cap: 6B EUR

Relative Value

There is not enough data to reliably calculate the relative value of 2R3.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

2R3 Relative Value
Base Case
Not Available
R
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
286.7
Median 5Y
286.7
Industry
2.7
vs History
vs Industry
Median 3Y
-75.1
Median 5Y
-43.6
Industry
21.6
vs History
vs Industry
Median 3Y
-26.5
Median 5Y
-25.5
Industry
16.9
vs History
vs Industry
Median 3Y
-36.9
Median 5Y
-32.7
Industry
22.9
vs History
vs Industry
Median 3Y
75.5
Median 5Y
72.4
Industry
2.3
vs History
vs Industry
Median 3Y
275.7
Median 5Y
271.5
Industry
3
vs History
vs Industry
Median 3Y
288.9
Median 5Y
162.7
Industry
5.6
vs History
vs Industry
Median 3Y
-18.6
Median 5Y
-17.8
Industry
13.4
vs History
vs Industry
Median 3Y
-18.5
Median 5Y
-17.7
Industry
16.7
vs History
vs Industry
Median 3Y
-25.5
Median 5Y
-24.4
Industry
16.1
vs History
vs Industry
Median 3Y
-25.4
Median 5Y
-24.3
Industry
18.9
vs History
vs Industry
Median 3Y
41.5
Median 5Y
41.5
Industry
2

Multiples Across Competitors

2R3 Competitors Multiples
Reata Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Reata Pharmaceuticals Inc
F:2R3
6.1B EUR 302.8 -81.1 -20.1 -20.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
504.6B USD 5.5 20.1 16.4 21.3
CH
Roche Holding AG
SIX:ROG
271.1B CHF 4.4 28.7 12.2 14.3
UK
AstraZeneca PLC
LSE:AZN
217.4B GBP 5 31.1 109.3 159.9
US
Merck & Co Inc
NYSE:MRK
271.6B USD 4.2 14.3 10.1 12
CH
Novartis AG
SIX:NOVN
218.1B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.5 11.4 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.7B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
US
R
Reata Pharmaceuticals Inc
F:2R3
Average P/E: 25
Negative Multiple: -81.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.1
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.3
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.5
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
R
Reata Pharmaceuticals Inc
F:2R3
Average EV/EBITDA: 440.1
Negative Multiple: -20.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
109.3
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
R
Reata Pharmaceuticals Inc
F:2R3
Average EV/EBIT: 1 883.8
Negative Multiple: -20.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.9
23%
7
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5